Choose Your Language:
Posted by: The Sumaira Foundation in News & Announcements
August 16, 2022 – The Sumaira Foundation (TSF) is please to announce a partnership with The Assistance Fund (TAF) to help people living in the US with neuromyelitis optica spectrum disorder (NMOSD) by providing financial assistance and support services for patients and their caregivers or loved ones.
The Assistance Fund (TAF) helps patients and families facing high medical out-of-pocket costs by providing financial assistance for copayments, coinsurance, deductibles, and other health-related expenses. Since its funding in 2009, TAF has helped more than 160,000 children and adults in all 50 states, Washington, DC, and Puerto Rico.
“As someone who has been listening and learning from the NMOSD community for nearly a decade, I am encouraged to partner with TAF, a patient assistance program specifically designed for patients who face challenges related to accessing and securing treatment,” said TSF Founder and Executive Director Sumaira Ahmed. “The key to managing NMOSD is to start and stay on a treatment plan to prevent relapses, and we are thrilled to partner with TAF to help people around the U.S. afford their treatment, as well as access the support services and community they need and deserve along the way.”
Patients who qualify for the TAF Neuromyelitis Optica Spectrum Disorder Financial Assistance Program are eligible for coverage for out-of-pocket expenses and other health-related services. Once a patient is enrolled in a disease program, their coverage lasts the entire calendar year, and there is no cap on the amount of assistance in that calendar year.
Eligibility criteria:
To get financial assistance for neuromyelitis optica spectrum disorder, patients must:
About The Assistance Fund
In 2019, The Assistance Fund opened a Neuromyelitis Optica Spectrum Disorder Financial Assistance Program to help patients with coverage for out-of-pocket expenses related to neuromyelitis optica spectrum disorder (NMOSD). Covered expenses include prescription drug assistance on FDA-approved treatment, health insurance premiums, therapy administration costs, disease management, treatment-related travel costs, and diagnostic laboratory tests. There is no cap on the amount of assistance a patient receives in a calendar year after they are approved and enrolled in a TAF disease program. Apply Today
